Cofactor Genomics involves in predictive diagnostics within the biotechnology sector, focusing on the development of tools that utilize RNA sequencing technology to predict patient responses to immunotherapy treatments. The company offers products that analyze pre-treatment tumor biopsies to assess the effectiveness of immunotherapy for various solid tumor cancers. Cofactor Genomics serves the healthcare industry, with a focus on cancer. It was founded in 2008 and is based in San Francisco, California.

Cadex Genomics is a company focused on the development of blood-based assays for cancer therapy monitoring. Their main offering, Alibrex, is a blood test that identifies disease progression in stage IV cancer patients, allowing for treatment adjustments. The company primarily serves the healthcare sector, providing oncologists with tools to make decisions about cancer treatment. It was founded in 2018 and is based in Redwood City, California.

NanoString Technologies serves as a provider of life science tools for translational research, focusing on spatial biology and gene expression analysis. The company offers a range of products based on digital molecular barcoding technology for applications such as gene expression analysis, microRNA analysis, and copy number variation detection. Its platforms enable highly-multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE and fresh frozen tissues, at cellular and subcellular resolution. It was founded in 2003 and is based in Seattle, Washington. In February 2024 NanoString Technologies filed for bankruptcy.

Foundation Medicine offers cancer care treatments. It develops an informative genomic profile to identify a patient's individual molecular alterations and match with relevant targeted therapies and clinical trials. It was founded in 2010 and is based in Cambridge, Massachusetts. Foundation Medicine was formerly known as Foundation Genomics. In June 2018, Foundation Medicine was acquired by Roche Holdings.

Veracyte (NASDAQ: VCYT) is a global diagnostics company that focuses on providing insights for cancer diagnosis and treatment. The company offers a suite of molecular tests and genomic classifiers designed to assist clinicians in making informed decisions, thereby helping patients avoid unnecessary procedures and receive timely treatment. Veracyte's products are utilized across various sectors of the healthcare industry, including oncology and personalized medicine. It was founded in 2008 and is based in South San Francisco, California.

Guardant focuses on oncology, providing blood and tissue tests to aid in cancer diagnosis and management. The company offers products including blood tests for early-stage and advanced-stage cancer detection, as well as tissue molecular profiling. It primarily serves the healthcare sector. The company was founded in 2012 and is based in Palo Alto, California.